GSK: reacts to California court decision

(CercleFinance.com) - In the wake of the California state court's decision on the Goetz case, GSK said it "respectfully disagrees" with the court's ruling.

The company states that "Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer".

GSK points out that the litigation is still in its early stages and that yesterday's decision only addresses the issue of whether the plaintiff's experts can testify at the trial in the Goetz case.

This does not mean that the court agrees with the scientific conclusions of the plaintiff's experts, GSK says, assuring that it will raise additional defences and adding that "the plaintiff still needs to prove his case at trial".

This decision does not affect the other state cases or the December 2022 Daubert decision in the federal multidistrict litigation, the company said.


Copyright (c) 2023 CercleFinance.com. All rights reserved.